Value Based Payment (VBP) for Pharmaceuticals

Similar documents
PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING

CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting

Welcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE

TECHNICAL APPENDIX 1 THE FUTURE ELDERLY MODEL

Value-Based Insurance Design. Using Smarter Cost-sharing to Align Consumer Incentives with Alternative Payment Models

Value-based Contracting: Chief Medical Officer and Actuarial Perspectives

PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches

Risk-Sharing Agreements in the U.S.: Trends, Barriers & Prospects

EHR Trends: PA patterns in situ. Evan Grossman Vice President Integration Services

Market Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement

Pay for Performance & the Changing Landscape for Pharmacy: A Panel Discussion

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry

RISK SHARE AGREEMENTS

REWARDING RESULTS. Moving Forward on Value-Based Contracting for Biopharmaceuticals

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis

Get a 1-month supply of ENTRESTO at no cost to you *

Payer Channel Forecasting and Analysis. Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc.

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

Pay as little as a $10 co-pay a month for ENTRESTO *

Members: Abbott, Blue Cross Blue Shield of Massachusetts, Boston Scientific Corporation, Genentech, Inc., Medtronic, Inc., Premier, Inc.

PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES

ICER Value Assessment Framework: 1.0 to 2.0

THIRD-PARTY PHARMACY RECONCILIATION

Co-Pay Incentives: Medicare Advantage (Part D) Can Replicate Successes of Commercial Payers

Provide sufficient incentive for providers to maximize health outcomes and value while reducing costs;

Delivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer

The Management of Specialty Drugs: Opportunities and Challenges

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR EMPLOYERS

Healthcare Reform and Its Impact on the Care Delivery System

Medicaid Prescribed Drug Program Spending Control Initiatives. For the Quarter April 1, 2014 through June 30, 2014

Moving From Offers to Solutions

June 25, Seema Verma Administrator Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

Prescription Medicines: Costs in Context. Updated August 2016

Avalere Health 2015 Industry Outlook

Aligning health plans and providers: Working together to control costs

Real-Time Benefit Check (RTBC) Solution Assessment. Requirements for selecting the most valuable RTBC solution for your health system

Value-Based Insurance Design. Potential Role in Depression

Supreme Court Ruling on the Affordable Care Act (ACA): Overview & Implications

Re: Department of Health and Human Services: Promoting Healthcare Choice and Competition Across the United States

ASSESSING THE VALUE OF MEDICAL DEVICES CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE? Drew Baker GO FROM HERE?

Centers for Medicare & Medicaid Services: Innovation Center New Direction Request For Information: Medicare Advantage (MA) Innovation Models

The Estonian Health Insurance System

Improving health care affordability Helping health plans bend the cost curve

Get a 1-month supply of ENTRESTO at no cost to you*

REPORT 8 OF THE COUNCIL ON MEDICAL SERVICE (I-11) Administrative Simplification in the Physician Practice (Reference Committee J) EXECUTIVE SUMMARY

ECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY. Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx

January 31, Dear Mr. Larsen:

Fourth Quarter 2018 Earnings Conference Call

Accountability: Hospital and Health System Pricing. Introduction. David V. Axene, FSA, CERA, FCA, MAAA

Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]

LARGE SIMPLE CLINICAL TRIALS IN INSURANCE SYSTEMS POST-MYOCARDIAL INFARCTION FREE RX EVENT AND ECONOMIC EVALUATION (MI FREEE) TRIAL

The Real Deal About Real-Time Benefits. Proven Savings with Up-to-the-Minute, Member-Specific Information Across Multiple Points of Care

FEEL BETTER. CONNECTED.

Enhancing Value in the Military Health System: Using 'Clinical Nuance' to Align Provider and Consumer Incentives

National Grid Retiree Club Meeting Long Island. October 2, 2017

Blockchain in Health Is it Hype or Real?

April 8, Dear Mr. Levinson,

PI Compensation: Methods, Documentation, and Execution

PI Compensation: Methods, Documentation, and Execution

ICLIO National Conference

Health Care Resources: Costs. Peterson-Kaiser Health System Tracker

Florida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter October 1, 2017 through December 31, 2017

MedTech Innovation Amid Changing Dynamics for Insurers, Hospitals, and Consumers

Prescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007

Insightsfeature. Managing Specialty Drug Spend Under the Medical Benefit. Innovations and Automation for More Effective Management.

Health care affordability VBC transformation

Kansas Health Policy Authority State of Health Reform in Kansas Kansas Economic Policy Conference October 30, 2008

Corporate Plan

MEDTRONIC AND VALUE-BASED HEALTHCARE: PARTNERING TO IMPROVE OUTCOMES AT LOWER COST

The Landscape of Medicaid Value-based Purchasing

Public and Private Payer Responses to Pharmaceutical Pricing in the United States

AccessCUBICIN Enrollment Form

Will Health Plans Kill the Laboratory Outreach Program?

RE: Proposed Rule: RIN 0906-AA90, 340B Drug Pricing Program; Administrative Dispute Resolution, (Vol. 81, No. 156, August 12, 2016)

GENERIC DRUG SAVINGS IN THE U.S.

Transition to Value-Based Health Care: Challenges and Opportunities for the Pharmaceutical Industry. June 7, 2017

11/1/2016. Molina Healthcare of Michigan. Prior Authorizations. Third Party Payer Day Julie Hurst. Director, Provider Contracting and Services

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT

Evidence-Based Program Reimbursement Strategies. Timothy P. McNeill, RN, MPH

MACRA, MIPS, APMs & CPC+: What to Expect from All These Acronyms?! Monthly National Briefing April 26, 2016

Recent Developments In U.S. Pharmaceutical Pricing: The Case Example Of The Proposed Medicare Part B Experiment

The Impact of Future Healthcare Reform on MedTech Communications

Building Clinical Trial Revenue Integrity Compliance Through Auditing and Understanding Payer Requirements

Blockchain in Health Is it Hype or Real?

MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013

April 8, 2019 VIA Electronic Filing:

A PROVEN FORMULA FOR BETTER OUTCOMES

OCM 2.0 THE JOURNEY AHEAD. Panel Moderator: Kavita Patel, MD, MS Tuple Health

Marc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance

New Rules, New Opportunities: Medicaid Managed Care Regulations

Florida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter July 1, 2016 through September 30, 2016

Initiative Options for Simulation Scenarios

Policy Proposals for Reducing Health Care Costs. Marc Boutin, JD Chief Executive Officer

Reference Pricing Reduces Employer and Employee Spending for Magnetic Resonance Imaging (MRI) Scans

Medicare s s 2009 eprescribing Program

Moral Hazard Lecture notes

hfma September 21, 2018

THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL INTRODUCED BY WHITE, STREET, BARTOLOTTA, COSTA, FONTANA AND BREWSTER, APRIL 18, 2017 AN ACT

Stuart H. Altman. The Changing Health Care System: Economic Forces Pushing States To Become More Involved

Transcription:

Value Based Payment (VBP) for Pharmaceuticals David B. Nash, MD, MBA Dean Jefferson College of Population Health 901 Walnut Street 10 th Floor Philadelphia, PA 19107 215-955-6969 (Office) 215-923-7583 (Fax) david.nash@jefferson.edu jefferson.edu/populationhealth blogs.jefferson.edu/nashhealthpolicy.com www.facebook.com/jeffersonjcph twitter.com/jeffersonjcph

Objectives Describe the need for value based pricing in reimbursement Understand and evaluate current examples of value based pricing of pharmaceuticals Provide a pathway for stakeholders involved to move forward and improve upon value based pricing

Why is VBP in pharmaceutical reimbursement important?

Where are we and how did we get here?

Prescription Drug Trends Visualizing Health Policy: Recent Trends in Prescription Drug Costs. Kaiser Family Foundation, Apr 2016. http://www.kff.org/infographic/visualizing-health-policy-recent-trends-in-prescription-drug-costs/

What is value and who defines it?

Current Landscape

What do Value-Based Pricing Agreements Look Like?

Indication-Specific Pricing Effects of Uniform Pricing versus Indication-Based Pricing Chandra, A., & Garthwaite, C. (2017). The economics of indication-based drug pricing. N Engl J Med, 377(2), 103-106. doi:10.1056/nejmp1705035

What do Value-Based Pricing Agreements Look Like? Outcomes-based contract for Januvia & Janumet. Merck's rebates are based on drugs' ability to help T2DM population achieve or maintain treatment objectives AetnaCare collaboration to support treatment adherence, meet social support needs, and promote healthy lifestyle behaviors in T2DM and HTN patients

What do Value-Based Pricing Agreements Look Like? Michigan Outcomes-based contract for Avastin in NSCLC patients. The shorter the PFS in a patient, the greater the rebate to Priority Health. If patient remained progression-free for over 6 months, no rebate Data came from claims, imaging, & EHR. Genentech supported Priority Health s internal team with team of medical and privacy professionals

What do Value-Based Pricing Agreements Look Like? 1st outcomes-based contract to cover Medicaid patients. Contract covers select MS drugs Milestone in pharma/patient/payer partnership in VBC, especially for complex, high-cost conditions like MS

What do Value-Based Pricing Agreements Look Like? 2015 outcomes-based contract (pay-for-performance): Amgen provides discount to Harvard Pilgrim if (1) reduced LDL-C levels in Repatha patients is lower than results seen in clinical trials (2) drug utilization exceeds certain levels 2017 contract (CV outcomes): Harvard Pilgrim receives full refund if patient is hospitalized with MI or stroke after taking Repatha for 6+ months & is compliant with medication

What do Value-Based Pricing Agreements look like?

Future Outlook

Robinson JC, Whaley CM, Brown TT. Association of Reference Pricing with Drug Selection and Spending. N Engl J Med. 2017;377:658-665. doi: 10.1056/NEJMsa1700087

Data Needs for the Future Data Platforms Complex infrastructure required to collect big data Implementation is costly and requires robust IT system Personal EMRs may become another platform for data collection Realistic Outcomes Start with simple, attainable outcomes Adapt outcomes and contracts based on clinical relevance and availability Ex. PCSK9 inhibitors

Data Sharing and Transparency Need to share successes and failures Transparency would encourage others to become involved and see benefits of taking on risk

Future Engagement of All Stakeholders Involve patients & providers alongside manufacturer and payer Target patients who are members of integrated delivery systems or Accountable Care Organizations Provide incentives for patients who are compliant Managed care organizations take on more risk in the success of the contract Adherence, patient education, outof-pocket costs

Future Policy Issues Possible expansion of reference pricing Work with the existing pricing structure Medicaid Best Price, Medicare Part B, and 340 B are not all compatible with VBP arrangements Some states in the US are taking matters into their own hands to control drug prices